ContractaTYR PHARMA INC • December 22nd, 2014 • Biological products, (no disgnostic substances) • California
THIS WARRANT AND THE SHARES ISSUABLE HEREUNDER HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”), OR THE SECURITIES LAWS OF ANY STATE AND, EXCEPT AS SET FORTH IN SECTIONS 5.3 AND 5.4 BELOW, MAY NOT BE OFFERED, SOLD, PLEDGED OR OTHERWISE TRANSFERRED UNLESS AND UNTIL REGISTERED UNDER SAID ACT AND LAWS OR IN FORM AND SUBSTANCE SATISFACTORY TO THE COMPANY, SUCH OFFER, SALE, PLEDGE OR OTHER TRANSFER IS EXEMPT FROM SUCH REGISTRATION.
LEASE by and between BMR-John Hopkins Court LLC, a Delaware limited liability company and aTyr Pharma, Inc., a Delaware corporationLease • December 22nd, 2014 • aTYR PHARMA INC • Biological products, (no disgnostic substances) • California
This letter concerns that certain Lease dated as of December [ ], 2011 (the “Lease”), between BMR-John Hopkins Court LLC (“Landlord”) and aTyr Pharma, Inc. (“Tenant”). Capitalized terms not otherwise defined herein shall have the meanings given them in the Lease.
EMPLOYMENT AGREEMENTEmployment Agreement • December 22nd, 2014 • aTYR PHARMA INC • Biological products, (no disgnostic substances) • California
This Employment Agreement (this “Agreement”) is made by and between aTyr Pharma, Inc., a Delaware corporation (the “Company”), and John D. Mendlein (“Employee”).
April 28, 2011 Melissa Ashlock, M.D. Dear Melissa:aTYR PHARMA INC • December 22nd, 2014 • Biological products, (no disgnostic substances)
This letter is a formal offer setting forth the principal terms for you to join aTyr Pharma, Inc. (the “Company”), a Delaware corporation, which is located in San Diego, California.
MASTER SERVICES AGREEMENT BETWEEN ATYR PHARMA, INC. AND SYNGENE INTERNATIONAL LIMITEDMaster Services Agreement • December 22nd, 2014 • aTYR PHARMA INC • Biological products, (no disgnostic substances) • New York
Whereas, Syngene is an integrated research service provider in the fields of biology and chemistry from early discovery stages through process development and custom manufacturing;
WARRANT TO PURCHASE STOCKaTYR PHARMA INC • December 22nd, 2014 • Biological products, (no disgnostic substances) • California
THIS WARRANT TO PURCHASE STOCK (“WARRANT”) CERTIFIES THAT, for good and valuable consideration, the receipt of which is hereby acknowledged, COMERICA BANK, a Michigan banking corporation, or its assignee (“Holder”), is entitled to purchase the number of fully paid and nonassessable shares of the class of securities (the “Shares”) of ATYR PHARMA, INC. (the “Company”) at the initial exercise price per Share (the “Warrant Price”) all as set forth above and as adjusted pursuant to this Warrant, subject to the provisions and upon the terms and conditions set forth in this Warrant. At such time as Company requests the initial advance under the Growth Capital Line, as defined in the Loan and Security Agreement between the Holder and the Company dated as of the date hereof, and the Holder has delivered such funds to the Company (or such account as may be directed by the Company), the Number of Shares issuable hereunder shall increase by an additional 36,000 shares of Series B Preferred Stock.
LOAN AND SECURITY AGREEMENTLoan and Security Agreement • December 22nd, 2014 • aTYR PHARMA INC • Biological products, (no disgnostic substances) • Delaware
THIS LOAN AND SECURITY AGREEMENT (this “Agreement”) dated as of April 25, 2012 (the “Effective Date”) between SILICON VALLEY BANK, a California corporation (“Bank”), and ATYR PHARMA, INC., a Delaware corporation (“‘Borrower”), provides the terms on which Bank shall lend to Borrower and Borrower shall repay Bank. The parties agree as follows:
